Orkambi is an experimental drug for the treatment of cystic fibrosis developed by Vertex Pharmaceuticals. The drug is designed to be effective in patients that have the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR ), the defective protein that causes the disease. F508del, meaning that the amino acid phenylalanine in position 508 is missing, is found in about 60% of cystic fibrosis patients in Europe, and in about 90% of persons with some mutation in the CFTR gene.
Strength: Ivacaftor 125 Mg / Lumacaftor 200 Mg
Pill Imprint: 2V125
Shape: Elliptical / Oval
View Images & Details